FDA Approval Alert: The Need-to-Know | Adjuvant Pembrolizumab for Resected NSCLC

In January 2023, the FDA approved adjuvant pembrolizumab for the treatment of completely resected non-small cell lung cancer.

An expert from Yale School of Medicine discusses how the approval of adjuvant pembrolizumab expands treatment to include patients with IB, II, III, and IIIA resected, early-stage, non–small cell lung cancer regardless of PD-L1 expression.
Adjuvant Pembrolizumab Approval Adds to Prevention of Recurrent NSCLC
Video
Feb 2, 2023 7:00 PM
An expert from Yale School of Medicine discusses how the approval of adjuvant pembrolizumab expands treatment to include patients with IB, II, III, and IIIA resected, early-stage, non–small cell lung cancer regardless of PD-L1 expression.
The FDA approved adjuvant pembrolizumab for the treatment of patients with resected non–small cell lung cancer, based on data from the phase 3 KEYNOTE-091/EORTC-1416-LCG/ETOP-8-15-PEARLS trial.
FDA OKs Adjuvant Pembrolizumab for Resected NSCLC
Article
Jan 26, 2023 11:23 PM
The FDA approved adjuvant pembrolizumab for the treatment of patients with resected non–small cell lung cancer, based on data from the phase 3 KEYNOTE-091/EORTC-1416-LCG/ETOP-8-15-PEARLS trial.